Samuel Potolicchio, MD
Neurological Surgery · Bethesda, MDNPI 1114993367
Payments from drug & device makers
Across 236 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$873
- AbbVie$591
- Axsome Therapeutics, Inc.$352
- Novartis$330
- Lilly USA, LLC$276
- Harmony Biosciences LLC$210
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,42696%
- Education$1774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 55 | $873 |
| AbbVie(2 entities) | 29 | $591 |
| Axsome Therapeutics, Inc. | 18 | $352 |
| Novartis | 17 | $330 |
| Lilly USA, LLC | 15 | $276 |
| Harmony Biosciences LLC | 8 | $210 |
| Livanova USA, Inc. | 4 | $185 |
| UCB, Inc. | 13 | $180 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $143 |
| Biogen | 6 | $110 |
| Bristol Myers Squibb | 5 | $107 |
| Sunovion Pharmaceuticals Inc. | 5 | $94 |
| Eisai Inc. | 5 | $89 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Johnson & Johnson | 2 | $67 |
| GE HealthCare | 2 | $65 |
| Sanofi | 3 | $64 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Grifols USA, LLC | 2 | $51 |
| SK Life Science, Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Lundbeck LLC | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Genentech USA, Inc. | 3 | $49 |
| Pfizer | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Neuropace, Inc. | 1 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $29 |
| Neurelis, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Amgen | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| AstraZeneca | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Argenx US, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$139
How this compares
$4,603 in reported general payments places this provider in the 45th percentile of 133 neurological surgery providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $296,981 |
| AptiomEslicarbazepine Acetate | 15 | $42,668 |
| Rufinamide | 15 | $30,481 |
| UbrelvyUbrogepant | 21 | $25,749 |
| Keppra XrLevetiracetam | 11 | $23,761 |
| Nurtec OdtRimegepant Sulfate | 15 | $16,273 |
| DepakoteDivalproex Sodium | 24 | $11,237 |
| Lamotrigine ErLamotrigine | 12 | $8,961 |
| Effexor XrVenlafaxine Hcl | 13 | $7,131 |
| Lacosamide | 24 | $6,034 |
| DilantinPhenytoin Sodium Extended | 25 | $5,376 |
| Propranolol Hcl ErPropranolol Hcl | 52 | $2,597 |
| Memantine Hcl | 96 | $2,055 |
| Carbamazepine | 27 | $2,031 |
| Levetiracetam | 53 | $1,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $51 | $296,98128 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $94 | $42,66815 claims |
| PfizerNurtec Odt, Effexor Xr, Dilantin | $44 | $28,78053 claims |
| AbbVieUbrelvy | $591 | $25,74921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 133 neurological surgery providers in Maryland.
Other neurological surgery in Bethesda
- Louis ChangBethesda$72K
- Edjah NduomBethesda$18K
- Kristopher HootenBethesda$17K
- Zachary LevineBethesda$14K
- Judy HuangBaltimore$4.2M
- Alexander CoonBaltimore$2.9M
- Faheem SandhuClinton$2M
- Charles SansurBaltimore$1.8M
- Howard EisenbergBaltimore$1.5M
- Graeme WoodworthBaltimore$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.